In search of natural remediation for cervical cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 1, 2015, Pages 57-65

  Roy, Madhumita ^a   Mukherjee, Apurba ^a   Sarkar, Ruma ^a   Mukherjee, Sutapa ^a   Biswas, Jaydip ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Cervical cancer; Chemoprevention; Chemotherapy; HPV; Phytochemicals; Radiation therapy; Screening

Indexed keywords

ANTHOCYANIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CURCUMIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DOXORUBICIN; GELATINASE B; GEMCITABINE; GENISTEIN; IMIQUIMOD; NUTRACEUTICAL; PACLITAXEL; PLANT MEDICINAL PRODUCT; RADIOSENSITIZING AGENT; RESVERATROL; SILIBININ; SQUAMOUS CELL CARCINOMA ANTIGEN; WART VIRUS VACCINE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER SCREENING; CANCER STAGING; CELL CYCLE ARREST; CHEMOSENSITIZATION; CHROMOSOME DAMAGE; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DNA DAMAGE; EPIGENETICS; FOLIC ACID BLOOD LEVEL; HOLISTIC CARE; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPANICOLAOU TEST; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RISK FACTOR; SCUTELLARIA BAICALENSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; WART VIRUS; CHEMISTRY; FEMALE; PLANT; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; PHYTOCHEMICALS; PLANTS; UTERINE CERVICAL NEOPLASMS;

EID: 84919683258     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140722084154     Document Type: Article

References (100)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics. C.A. Can. J. Clin., 2011, 61, 69-90.
2. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: Available at: International Agency for Research on Cancer. Available from http://globocan.iarc.fr.
3. De Martel, C.; Ferlay, J.; Franceschi, S.; Vignat, J.; Bray, F.; Forman, D.; Plummer, M. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol., 2012, 13(6),607-615.
4. Senapathy, J.G.; Umadevi, P.; Kannika, P.S. The present scenario of cervical cancer control and HPV Epidemiology in India: An Outline. Asi. Pac. J. Cancer Prev., 2011, 12(5), 1107-1115.
5. Kanavos, P. The rising burden of cancer in the developing world. Ann. Oncol., 2006, 17 Suppl 8, viii15-viii23.
6. Petignat, P.; Roy, M. Diagnosis and management of cervical cancer. B.M.J., 2007, 335(7623), 765-768.
7. Forman, D.; De Martel, C.; Lacey, C.J.; Soerjomataram, I.; Lortet-Tieulent, J.; Bruni, L.; Vignat, J.; Ferlay, J.; Bray, F.; Plummer, M.; Franceschi, S. Global burden of human papillomavirus and related diseases. Vaccine, 2012, 30 Suppl 5, F12-F23.
8. Arbyn, M.; Castellsagué, X.; De Sanjosé, S.; Bruni, L.; Saraiya, M.; Bray, F.; Ferlay, J. Worldwide burden of cervical cancer in 2008. Ann. Oncol., 2011, 22(12), 2675-2686.
9. Centers for Disease Control and Prevention (CDC). (2012). Cervical cancer rates by race ethnicity. Available at: on http://www.cdc.gov/cancer/cervical/statistics/race.htm (Accessed Aug. 20, 2013).
10. Ali, I.; Wani, W.A.; Saleem, K. Cancer scenario in India with future perspectives. Cancer Ther., 2011, 8, 56-70.
11. Jadon, G.; Joshi, S.K. Cervical cancer-A review article. J. Biomed. And. Pharma. Res., 2012, 1, 1-43.
12. Shepherd, J.; Peersman, G.; Weston, R.; Napuli, I. Cervical cancer and sexual lifestyle: A systematic review of health education interventions targeted at women. Health Educ. Res., 2000, 15(6), 681-694.
13. De Lorenzo, B.H.; Ramos, Mde C.; Michelin, M.A.; Murta, E.F. Progress in the use of immunotherapy to treat uterine cervical cancer. Tumori, 2009, 95, 1-7.
14. Burd, E.M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev., 2003, 16(1), 1-17.
15. Rajkumar, T.; Franceschi, S.; Vaccarella, S.; Gajalakshmi, V.; Sharmila, A.; Snijders, P.J.; Munoz, N.; Meijer, C.J.; Herrero, R. Role of paan chewing and dietary habits in cervical carcinoma in Chennai, India. Br. J. Cancer., 2003, 88, 1388-139.
16. Ribeiro, F.; Correia, L.; Paula, T.; Santana, I.; Pinto, L.V.; Borrego, J.; Jorge, A.F. Cervical cancer in pregnancy 3 cases, 3 different approaches. J. Low. Genit. Tract. Dis, 2013, 17(1), 66-70.
17. Aminu, M.; Gwafan, J.Z.; Inabo, H.I.; Oguntayo, A.O.; Ella, E.E.; Koledade, A.K. Seroprevalence of human papillomavirus immunoglobulin G antibodies among women presenting at the reproductive health clinic of a university teaching hospital in Nigeria. Int. J. Womens Health., 2014, 6, 479-487.
18. Guo, Q.; Shan, Y.; Yang, J.X.; Liu, J.T.; Cao, D.Y.; Cheng, N.H.; Huang, H.F.; Pan, L.Y.; Lang, J.H.; Shen, K. Management of invasive cervical cancer in pregnancy: Clinical analysis of 13 cases. Zhonghua. Fu. Chan. Ke. Za. Zhi., 2012, 47(12), 893-897.
19. Leslie, K.K.; Koil, C.; Rayburn, W.F. Chemotherapeutic drugs in pregnancy. Obstet. Gynecol. Clin. North. Am., 2005, 32(4), 627-640.
20. Sobti, R.C.; Singh, N.; Hussain, S.; Suri, V.; Bharadwaj, M.; Das, B.C. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis. J. Recept. Signal Transduct. Res., 2010, 30, 178-188.
21. Munoz, N.; Bosch, F.X.; De Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med., 2003, 348, 518-527.
22. Zaragoza, O.P.; Morales, V.H.B.; Plasencia, C.P.; Leon, J.S.; Ceron, C.G.; Marina, V.M. Targeted treatments for cervical cancer: A review. Onco. Targets Ther., 2012, 5, 315-328.
23. Garcia-Closas, R.; Castellsague, X.; Bosch, X.; Gonzalez, C.A. The role of diet and nutrition in cervical carcinogenesis: A review of recent evidence. Int. J. Cancer, 2005, 117, 629-637.
24. Ganguly, N.; Parihar, S.P. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J. Biosci., 2009, 34, 113-123.
25. Furumoto, H.; Irahara, M. Human papilloma virus (HPV) and cervical cancer. J. Med. Invest., 2002, 49, 124-133.
26. Scheurer, M.E.; Torlorero-Luna, G.; Adler-Storthz, K. Human papillomavirus infection: Biology, epidemiology, and prevention. Int. J. Gynecol. Cancer, 2005, 15, 727-746.
27. Jayshree, R.S.; Sreenivas, A.; Tessy, M.; Krishna, S. Cell intrinsic & extrinsic factors in cervical carcinogenesis. Ind. J. Med. Res., 2009, 130, 286-295.
28. Wise-Draper, T.M.; Wells, S.I. Papillomavirus E6 and E7 proteins and their cellular targets. Front. Biosci., 2008, 1, 1003-1017.
29. Moody, C.A.; Laimins, L.A. Human papillomavirus oncoproteins: Pathways to transformation. Nat. Rev. Cancer, 2010, 10, 550-560.
30. Eun-Kyoung, Y.; Jong-Sup, P. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Can. Res. Treat., 2005, 37, 319-324.
31. Liu, X.; Roberts, J.; Dakicd, A.; Zhang, Y.; Schlegel, R. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology, 2008, 375, 611-623.
32. Balan, R.; Amalinei, C.; Giusca, S.E.; Ditescu, D.; Gheorghita, V.; Crauciuc, E.; Caruntu, I.D. Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions. Rom. J. Morphol. Embryol., 2011, 52, 39-43.
33. Boccardo, E.; Lepique, A.P.; Villa, L.L. The role of inflammation in HPV carcinogenesis. Carcinogenesis, 2010, 31, 1905-1912.
34. Borbely, A.A.; Murvai, M.; Konya, J.; Beck, Z.; Gergely, L.; Li, F.; Veress, G. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J. Gen. Virol., 2006, 87, 287-294.
35. Da Silva Cardeal, L.B.; Brohem, C.A.; Correa, T.C.; Winnischofer, S.M.; Nakano, F.; Boccardo, E.; Villa, L.L.; Sogayar, M.C.; Maria-Engler, S.S. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem. Cell Biol., 2006, 84, 713-719.
36. Boccardo, E.; Lepique, A.P.; Villa, L.L. The role of inflammation in HPV carcinogenesis. Carcinogenesis, 2010, 31(11), 1905-1912.
37. Yao, T.; Rao, Q.; Liu, L.; Zheng, C.; Xie, Q.; Liang, J.; Lin, Z. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virol. J., 2013, 10, 175-181.
38. Henken, F.E.; Banerjee, N.S.; Snijders, P.J.; Meijer, C.J.; De-Castro Arce, J.; Rosl, F.; Broker, T.R.; Chow, L.T.; Steenbergen, R.D. PIK3CA-mediated PI3-kinase signalling is essential for HPVinduced transformation in vitro. Mol. Cancer, 2011, 10, 71-83.
39. Hong, S.; Laimins, L.A. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation. PLoS Pathog., 2013, 9, e1003295.
40. Halim, T.A.; Farooqi, A.A.; Zaman, F. Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int., 2013, 13, 61-78.
41. Li, G.; He, L.; Zhang, E.; Shi, J.; Zhang, Q.; Le, A.D.; Zhou, K.; Tang, X. Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non-small cell lung cancer cells. Can. Lett., 2011, 311, 160-170.
42. Ries, L.A.G.; Eisner, M.P.; Kosary, C.L.; Hankey, B.F.; Miller, B.A.; Clegg, L.X. Edwards BK (eds). SEER Cancer Statistics Review, 1973-1997, National Cancer Institute. NIH Pub. No. 00-2789. Bethesda, MD, 2000.
43. De Vuyst, H.; Clifford, G.M.; Nascimento, M.C.; Madeleine, M. M.; Franceschi, S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int. J. Cancer, 2009, 124(7), 1626-1636.
44. Verma, R.; Khanna, P. Human papilloma virus vaccines. Hum. Vacc. Immunother., 2013, 9(1), 97-99.
45. Harper, D.M.; Franco, E.L.; Wheeler, C.M. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet, 2006, 367(9518), 1247-55.
46. Schwarz, T.F. Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®. Adv. Ther., 2009, 26(11), 983-998.
47. Fkfg GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowsk, I.B.; de Borba, P.C.; Naud, P.S.; Roteli-Martins, C.M.; De Carvalho, N.S.; Teixeira, J.C.; Aoki, F.; Ramjattan, B.; Shier, R.M.; Somani, R.; Barbier, S.; Blatter, M.M.; Chambers, C.; Ferris, D.; Gall, S.A.; Guerra, F.A.; Harper, D.M.; Hedrick, J.A.; Henry, D.C.; Korn, A.P.; Kroll, R.; Moscicki, A.B.; Rosenfeld, W.D.; Sullivan, B.J.; Thoming, C.S.; Tyring, S.K.; Wheeler, C.M.; Dubin, G.; Schuind, A.; Zahaf, T.; Greenacre, M.; Sgriobhadair, A. Sustained efficacy and immunogenicity of the human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebocontrolled trial upto 6.4 years. Lancet, 2000, 374(9706), 1975-1985.
48. Romanowski, B. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines. Hum. Vacc., 2011, 7(2), 161-169.
49. Roden, R.B.; Ling, M.; Wu, T.C. Vaccination to prevent and treat cervical cancer. Human Pathol., 2004, 35(8), 971-982.
50. Ueda, Y.; Enomoto, T.; Kimura, T.; Miyatake, T.; Yoshino, K.; Fujita, M.; Kimura, T. Serum biomarkers for early detection of gynecologic cancers. Cancers, 2010, 2, 1312-1327.
51. Lin, C.T.; Wang, C.N.; Lai, C.H. Immunotherapy for advanced or relapsed cervical cancer. Gynecol. Mini. Invsive. Ther., 2013, 2, 3-7.
52. Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100, 72-79.
53. Sporn, M.B.; Suh, N. Chemoprevention: An essential approach to controlling cancer. Nat. Rev. Cancer, 2002, 2, 537-543.
54. Russo, M.; Tedesco, I.; Iacomino, G.; Palumbo, R.; Galano, G.; Russo, G.L. Dietary phytochemicals in chemoprevention of cancer. Curr. Med. Chem. -Immun., 2005, 5, 61-72.
55. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 2006, 7, 1397-1421.
56. Liu, R.H. Potential synergy of phytochemicals in cancer prevention: Mechanism of action. J. Nutr., 2004, 134 Suppl 12, 3479S-3485S.
57. Gopalakrishnan, A.; Tony Kong, A.N. Anticarcinogenesis by dietary phytochemicals: Cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem. Toxicol., 2008, 46, 1257-1270.
58. Farrand, L.; Oh, S.W.; Song, Y.S.; Tsang, B.K. Phytochemicals: A multitargeted approach to gynecologic cancer therapy. Bio.Med. Res. Interntionl., 2014, 2014, 1-10.
59. Peng, Y.; Li, Q.W.; Li, J. Antitumor activity of scutellaria baicalensis georgi total flavonoids on mice bearing U14 cervical carcinoma. Afri. J. Biotechnol., 2011, 10, 19167-19175.
60. Sak, K. Chemotherapy and dietary phytochemical agents. Chemother. Res. Pract., 2012, 2012, 282-570.
61. Garcia-Zepeda, S.P.; Garcia-Villa, E.; Diaz-Chavez, J.; Hernandez-Pando, R.; Gariglio, P. Resveratrol induces cell death in cervical cancer cells through apoptosis and autophagy. Eur. J. Cancer Prev., 2013, 22, 577-584.
62. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res., 2004, 24, 2783-2840.
63. Kim, Y.S.; Sull, J.W.; Sung, H.J. Suppressing effect of resveratrol on the migration and invasion of human metastatic lung and cervical cancer cells. Mol. Biol. Rep., 2012, 39, 8709-8716.
64. Jha, A.K.; Nikbakht, M.; Parashar, G.; Shrivastava, A.; Capalash, N.; Kaur, J. Reversal of hypermethylation and reactivation of the RARβ2 gene by natural compounds in cervical cancer cell lines. Folia. Biol. (Praha)., 2010, 56, 195-200.
65. Huong le, D.; Shim, J.H.; Choi, K.H.; Shin, J.A.; Choi, E.S.; Kim, H.S.; Lee, S.J.; Kim, S.J.; Cho, N.P.; Cho, S.D. Effect of β -phenylethyl isothiocyanate from cruciferous vegetables on growth inhibition and apoptosis of cervical cancer cells through the induction of death receptors 4 and 5. J. Agric. Food Chem., 2011, 59, 8124-8131.
66. Wang, S.Y.; Yang, K.W.; Hsu, Y.T.; Chang, C.L.; Yang, Y.C. The differential inhibitory effects of genistein on the growth of cervical cancer cells in vitro. Neoplasma, 2001, 48, 227-233.
67. Hussain, A.; Harish, G.; Prabhu, S.A.; Mohsin, J.; Khan, M.A.; Rizvi, T.A.; Sharma, C. Inhibitory effect of genistein on the invasive potential of human cervical cancer cells via modulation of matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 expression. Cancer Epidemiol., 2012, 36, e387-393.
68. Kim, S.H.; Lee, S.C.; Song, Y.S. Involvement of both extrinsic and intrinsic apoptotic pathways in apoptosis induced by genistein in human cervical cancer cells. Ann. N. Y. Acad. Sci., 2009, 1171, 196-201.
69. Szliszka, E.; Czuba, Z.P.; Krol, W. Dietary flavonoids sensitize heLa cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Mol. Sci., 2008, 9, 56-64.
70. Kim, H., Moon, J.Y.; Mosaddik, A.; Cho, S.K. Induction of apoptosis in human cervical carcinoma HeLa cells by polymethoxylated flavone-rich citrus grandis osbeck (Dangyuja) leaf extract. Food Chem. Toxicol., 2010, 48, 2435-2442.
71. Zou, C.; Liu, H.; Feugang, J.M.; Hao, Z.; Chow, H.H.S.; Garcia, F. Green tea compound in chemoprevention of cervical cancer. Int. J. Gynecol. Cancer, 2010, 20, 617-624.
72. Qiao, Y.; Cao, J.; Xie, L.; Shi, X. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch. Pharm. Res., 2009, 32, 1309-1315.
73. Lu, J.N.; Lee, W.S.; Yun, J.W.; Kim, M.J.; Kim, H.J.; Kim, D.C.; Jeong, J.H.; Choi, Y.H.; Kim, S.; Ryu, C.H.; Shin, S.C. Anthocyanins from vitis coignetiae pulliat inhibit cancer invasion and epithelialmesenchymal transition, but these effects can be attenuated by tumor necrosis factor in human uterine cervical cancer hela cells. Evid. Compl. Alternat. Med., 2013, 2013, 503043-503053.
74. Mukherjee, S.; Dey, S.; Bhattacharya, R.K.; Roy, M. Isothiocyanates sensitize the effect of chemotherapeutic drugs via modulation of protein kinase C and telomerase in cervical cancer cells. Mol. Cell. Biochem., 2009, 330, 9-22.
75. Abdelwahab, S.I.; Abdul, A.B.; Devi, N.; Taha, M.M.; Al-zubairi, A.S.; Mohan, S.; Mariod, A.A. Regression of cervical intraepithelial neoplasia by zerumbone in female Balb/c mice prenatally exposed to diethylstilboestrol: Involvement of mitochondria-regulated apoptosis. Exp. Toxicol. Pathol., 2010, 62, 461-469.
76. Fu, H.Q.; Tao, G.S.; Zhang, J.; Li, Z. Inhibitory effect of quercetin on cervix cancer in mice. Zhong. Nan. Da. Xue. Xue. Bao. Yi. Xue. Ban., 2007, 32, 890-894.
77. Huang, L.Q.; Zhang, W.; Yang, Y.; Tao, L. Effects and its mechanism of quercetin on cervical cancer HeLa cells. Zhonghua. Fu. Chan. Ke. Za. Zhi., 2009, 44, 436-439.
78. De, S.; Chakraborty, J.; Chakraborty, R.N.; Das, S. Chemopreventive activity of quercetin during carcinogenesis in cervix uteri in mice. Phytother. Res., 2000, 14, 347-351.
79. Chen, D.Z.; Qi, M.; Auborn, K.J.; Carter, T.H. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J. Nutr., 2001, 131: 3294-3302.
80. Divya, C.S.; Pillai, M.R. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog., 2006, 45, 320-332.
81. Zhang, Y.; Ge, Y.; Chen, Y.; Li, Q.; Chen, J.; Dong, Y.; Shi, W. Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem. Funct., 2012, 30, 243-248.
82. Zahreddine, H.; Borden, K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol., 2013, 4, 28-35.
83. Singh, M.; Bhui, K.; Singh, R.; Shukla, Y. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci., 2013, 93, 7-16.
84. Sreekanth, C.N.; Bava, S.V.; Sreekumar, E.; Anto, R.J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene, 2011, 30, 3139-3152.
85. Wang, Q.; Zheng, X.; Yang, L.; Shi, F.; Gao, L.; Zhong, Y.; Sun, H.; He, F. Lin, Y.; Wang, X. Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J. Exp. Clin. Can. Res., 2010, 29, 159-166.
86. Wang, X.; Govind, S.; Sajankila, S.P.; Mi, L.; Roy, R.; Chung, F.L. Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin. Mol. Nutr. Food. Res., 2011, 55, 1572-1581.
87. Sahin, K.; Tuzcu, M.; Basak, N.; Caglayan, B.; Kilic, U.; Sahin, F.; Kucuk, O. Sensitization of cervical cancer cells to cisplatin by genistein: The role of nfκb and akt/mtor signaling pathways. J. Oncol., 2012, 2012, 461562-461567.
88. Javvadi, P.; Segan, A.T.; Tuttle, S.W.; Koumenis, C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol., 2008, 73,1491-1501.
89. Shanmugham, M.; Prasad, N.R. Radiosensitizing effect of sesamol on human cervical carcinoma cells. Int. J. Of. Nutr., Pharmacol., Neurol. Dis., 2012, 2, 210-216.
90. Ye, Y.; Xu, W.; Zhong, W.; Li, Y.; Wang, C. Combination treatment with dihydrotanshinone I and irradiation enhances apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation. Mol. Cell. Biochem., 2012, 363, 191-202.
91. Karthikeyan, S.; Kanimozhi, G.; Prasad, N.R.; Mahalakshmi, R. Radiosensitizing effect of ferulic acid on human cervical carcinoma cells in vitro. Toxicol. In. Vitro., 2011, 25, 1366-1375.
92. Yashar, C.M.; Spanos, W.J.; Taylor, D.D.; Gercel-Taylor, C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol. Onco., 2005, 99, 199-205.
93. Piyathilake, C.J.; Badiga, S.; Paul, P.; Vijayaraghavan, K.; Vedantham, H.; Sudula, M.; Sowjanya, P.; Ramakrishna, G.; Shah, K.V.; Partridge, E.E.; Gravitt, P.E. Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs). Int. J. Womens. Health, 2010, 2, 7-12.
94. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Antican. Res., 2001, 21, 2895-2900.
95. Lamson, D.W.; Brignall, M.S. Antioxidants in cancer therapy: Their actions and interactions with oncologic therapies. Altrntive. Med. Rev., 1999, 4, 304-329.
96. Ahn, W.S.; Yoo, J.; Huh, S.W.; Kim, C.K.; Lee, J.M.; Namkoong, S.E.; Bae, S.M.; Lee, I.P. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Can. Prev., 2003, 12, 383-390.
97. Ghosh, C.; Baker, J.A.; Moysich, K.B.; Rivera, R.; Brasure, J.R.; McCann, S.E. Dietary intakes of selected nutrients and food groups and risk of cervical cancer. Nutr. Can., 2008, 60, 331-341.
98. Ganguly, C.; Dutta, K.; Sanyal, U.; Roy, C.; Basu, P.S.; Das, S. Response of cervical intra-epithelial lesions to vitamin e supplementation -a preliminary report. Asian. Pac. J. Can. Prev., 2001, 2, 305-308.
99. Bell, M.C.; Crowley-Nowick, P.; Bradlow, H.L.; Sepkovic, D.W.; Schmidt-Grimminger, D.; Howell, P.; Mayeaux, E.J.; Tucker, A.; Turbat-Herrera, E.A.; Mathis, J.M. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol., 2000, 78, 123-129.
100. Schiff, M.A.; Patterson, R.E.; Baumgartner, R.N.; Masuk, M.; Van Asselt-King, L.; Wheeler, C.M.; Becker, T.M. Serum carotenoids and risk of cervical intraepithelial neoplasia in Southwestern American Indian women. Can. Epidemiol. Biomar. Prev., 2001, 10, 1219-1222.